Synthesis of 213Bi-DOTA-Substance P for targeted alpha-radionuclide therapy in patients with malignant glioma

被引：0
|
作者：
Bruchertseifer, F. [1 ]
Cordier, D. [2 ]
Forrer, F. [3 ]
Kneifel, S. [3 ]
Apostolidis, C. [1 ]
Morgenstern, A. [1 ]
Merlo, A. [2 ]
Maecke, H. R. [3 ]
机构：
[1] Commiss European Communities, Joint Res Ctr, Inst Transuranium Elements, D-7500 Karlsruhe, Germany
[2] Univ Basel Hosp, Neurosurg Clin, CH-4031 Basel, Switzerland
[3] Univ Basel Hosp, Clin & Inst Nucl Med, CH-4031 Basel, Switzerland
来源：
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS | 2008年 / 23卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
02
引用
收藏
页码：513 / 513
页数：1
相关论文
共 37 条
  • [21] Locoregional Treatment of Glioblastoma With Targeted a Therapy [213Bi]Bi-DOTA-Substance P Versus [225Ac]Ac-DOTA-Substance P-Analysis of Influence Parameters
    Krolicki, Leszek
    Kunikowska, Jolanta
    Bruchertseifer, Frank
    Kulinski, Radoslaw
    Pawlak, Dariusz
    Koziara, Henryk
    Rola, Rafal
    Morgenstern, Alfred
    Merlo, Adrian
    CLINICAL NUCLEAR MEDICINE, 2023, 48 (05) : 387 - 392
  • [22] 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience
    C. Kratochwil
    F. L. Giesel
    F. Bruchertseifer
    W. Mier
    C. Apostolidis
    R. Boll
    K. Murphy
    U. Haberkorn
    A. Morgenstern
    European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41 : 2106 - 2119
  • [23] 225AC- and 213Bi-Substance P Analogues for Glioma Therapy
    Krolicki, Leszek
    Kunikowska, Jolanta
    Bruchertseifer, Frank
    Koziara, Henryk
    Krolicki, Bartosz
    Jakucinski, Maciej
    Pawlak, Dariusz
    Rola, Rafal
    Morgenstern, Alfred
    Rosiak, Elzbieta
    Merlo, Adrian
    SEMINARS IN NUCLEAR MEDICINE, 2020, 50 (02) : 141 - 151
  • [24] 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience
    Kratochwil, C.
    Giesel, F. L.
    Bruchertseifer, F.
    Mier, W.
    Apostolidis, C.
    Boll, R.
    Murphy, K.
    Haberkorn, U.
    Morgenstern, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 (11) : 2106 - 2119
  • [25] Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with 213Bi-substance P analogue
    Krolicki, Leszek
    Bruchertseifer, Frank
    Kunikowska, Jolanta
    Koziara, Henryk
    Krolicki, Bartosz
    Jakucinski, Maciej
    Pawlak, Dariusz
    Apostolidis, Christos
    Mirzadeh, Saed
    Rola, Rafal
    Merlo, Adrian
    Morgenstern, Alfred
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (09) : 1636 - 1644
  • [26] Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with 213Bi-substance P analogue
    Leszek Krolicki
    Frank Bruchertseifer
    Jolanta Kunikowska
    Henryk Koziara
    Bartosz Królicki
    Maciej Jakuciński
    Dariusz Pawlak
    Christos Apostolidis
    Saed Mirzadeh
    Rafał Rola
    Adrian Merlo
    Alfred Morgenstern
    European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45 : 1636 - 1644
  • [27] TARGETING OF MALIGNANT GLIOMAS WITH [BI-213]-LABELLED SUBSTANCE P-THE "ALPHA KNIFE" EXPERIENCE
    Cordier, D.
    Forrer, F.
    Kneifel, S.
    Mueller-Brand, J.
    Maecke, H.
    Merlo, A.
    NEURO-ONCOLOGY, 2008, 10 (06) : 1126 - 1126
  • [28] Targeted alpha therapy using [Bi-213]Substance P overcomes chemo- and radioresistance in glioblastoma and glioblastoma stem cells
    Friesen, C.
    Hormann, I.
    Roscher, M.
    Morgenstern, A.
    Bruchertseifer, F.
    Maecke, H.
    Fulda, S.
    Apostolidis, C.
    Debatin, K. -M.
    Miltner, E.
    ONKOLOGIE, 2010, 33 : 179 - 179
  • [29] In vitro evaluation of 225Ac-DOTA-substance P for targeted alpha therapy of glioblastoma multiforme
    Majkowska-Pilip, Agnieszka
    Rius, Maria
    Bruchertseifer, Frank
    Apostolidis, Christos
    Weis, Mirjam
    Bonelli, Milton
    Laurenza, Marta
    Krolicki, Leszek
    Morgenstern, Alfred
    CHEMICAL BIOLOGY & DRUG DESIGN, 2018, 92 (01) : 1344 - 1356
  • [30] Influence of tumour size on the efficacy of targeted alpha therapy with 213Bi-[DOTA0,Tyr3]-octreotate
    Ho Sze Chan
    Mark W. Konijnenberg
    Erik de Blois
    Stuart Koelewijn
    Richard P. Baum
    Alfred Morgenstern
    Frank Bruchertseifer
    Wouter A. Breeman
    Marion de Jong
    EJNMMI Research, 6
1234